ArticleThe Lancet. Infectious diseases2023
Tracking immune correlates of protection for emerging SARS-CoV-2 variants.
Article in The Lancet. Infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Statistical methods for estimating the protective effects of immune markers using test-negative designs.American journal of epidemiology · 2026Article
- Use of the test-negative design to estimate the protective effect of a scalar immune measure: a simulation analysis.American journal of epidemiology · 2026Article
- Acute Febrile Illness Surveillance for Estimating Population Immunity, Dominican Republic, 2021.Emerging infectious diseases · 2026Article
- A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples.The Journal of infectious diseases · 2026Article
- Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.The Journal of general virology · 2026Article
- SARS-CoV-2 SPIKE Antibody Levels can Indicate Immuno-Resilience to Re-infection: a Real-World Study.Infectious diseases and therapy · 2025Article
- Testing for SARS-CoV-2: lessons learned and current use cases.Clinical microbiology reviews · 2024Review
- Clinical Assessment of SARS-CoV-2 Antibodies in Oral Fluids Following Infection and Vaccination.Clinical chemistry · 2024Review
- Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.BMC medicine · 2024Article
- High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.The Journal of infectious diseases · 2023Article
- Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine.Human vaccines & immunotherapeutics · 2023Article
- Neutralization and binding antibody response to second bivalent COVID-19 vaccination in nursing home residents.Journal of the American Geriatrics Society · 2023Article
- Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response.Tropical medicine and infectious disease · 2023Article
- Long term anti-SARS-CoV-2 antibody kinetics and correlate of protection against Omicron BA.1/BA.2 infection.Nature communications · 2023Article
- Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19.Frontiers in public health · 2023Article
Corrections and comments
- Comment on
Authors and funding
12 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.